Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

BACKGROUND/AIM: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Turk J Med Sci
Autors principals: BATGİ, Hikmettullah, BAŞCI1, Semih, DAL1, Mehmet Sinan, KIZIL ÇAKAR, Merih, UNCU ULU, Bahar, YİĞENOĞLU, Tuğçe Nur, ÖZCAN, Nurgül, KILINÇ, Ali, MERDİN, Alparslan, YILDIZ, Jale, BAKIRTAŞ, Mehmet, ŞAHİN, Derya, DARÇIN, Tahir, İSKENDER, Dicle, BAYSAL, Nuran Ahu, ALTUNTAŞ, Fevzi
Format: Artigo
Idioma:Inglês
Publicat: The Scientific and Technological Research Council of Turkey 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8203130/
https://ncbi.nlm.nih.gov/pubmed/33237657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-2008-114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars